Skip to main content
德源药业 logo

德源药业 — Investor Relations & Filings

Ticker · 920735 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 569 across all filing types
Latest filing 2022-01-09 Regulatory Filings
Country CN China
Listing Beijing Stock Exchange 920735

About 德源药业

http://www.pharmdy.com

Deyuan Pharmaceutical specializes in the research, development, production, and commercialization of therapeutic drug preparations. The company focuses on chronic disease management, particularly in the fields of endocrinology and cardiovascular health. Its core product line includes treatments for diabetes, hypertension, and hyperlipidemia, featuring medications such as Metformin Hydrochloride sustained-release tablets, Pioglitazone Hydrochloride, and Valsartan. The organization emphasizes technological innovation and maintains rigorous quality control standards across its manufacturing processes. By leveraging advanced formulation technologies, the company develops high-efficacy pharmaceutical solutions aimed at addressing the long-term needs of patients with metabolic and circulatory disorders.

Recent filings

Filing Released Lang Actions
关于最近五年被证券监管部门和证券交易所（证券交易场所）处罚或采取监管措施及整改情况的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement from Jiangsu Deyuan Pharmaceutical Co., Ltd. regarding the company's status over the past five years with respect to penalties or regulatory measures imposed by securities regulatory authorities and stock exchanges. It explicitly states that the company has not been subject to any penalties or regulatory actions in the last five years. The document is short (690 characters) and serves as a compliance disclosure rather than a financial report or detailed regulatory filing. It does not contain financial data, audit results, or management discussion. It is a regulatory announcement about compliance status, fitting best under the category of Regulatory Filings (RNS).
2022-01-09 Chinese
关于向特定对象发行股票摊薄即期回报与填补措施及相关主体承诺的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by Jiangsu Deyuan Pharmaceutical Co., Ltd. regarding a specific issuance of shares to certain investors, including detailed analysis of the dilution impact on earnings per share, the necessity and rationale for the issuance, investment projects related to the raised funds, and commitments by the company's directors and controlling shareholders to measures mitigating dilution effects. The text references regulatory guidelines related to capital market health, issuance impact on shareholder returns, and includes financial assumptions and projections related to the share issuance. The document is focused on the issuance of new shares to specific parties and the related capital raising activities, rather than being a full financial report or earnings release. It is not a full annual or interim report, nor a call transcript or management discussion. The detailed discussion of the share issuance, its impact, and related commitments aligns with the category of Capital/Financing Update (CAP). The document length (7274 characters) and content indicate it is a substantive announcement rather than a brief notice or a report publication announcement. Therefore, the appropriate classification is CAP with high confidence.
2022-01-09 Chinese
第三届监事会第八次会议决议公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement of resolutions passed at the 8th meeting of the 3rd Supervisory Board of Jiangsu Deyuan Pharmaceutical Co., Ltd. It includes voting results on various proposals related to a specific capital raising activity: a targeted stock issuance. The content covers the meeting details, voting outcomes, and descriptions of the stock issuance plan, including pricing, quantity, use of proceeds, and lock-up arrangements. The document is not a full financial report but rather a formal announcement of board-level decisions regarding capital raising. It is not a shareholder meeting presentation or voting result declaration, but a supervisory board meeting resolution announcement. Given the content focuses on capital raising decisions and issuance plans, the most appropriate classification is Capital/Financing Update (CAP). The document length and detail confirm it is not a brief announcement or a simple regulatory filing. Confidence is high due to the specificity and detailed nature of the capital issuance discussion.
2022-01-09 Chinese
前次募集资金使用情况的专项报告
Capital/Financing Update Classification · 95% confidence The document is a detailed report on the usage of previously raised funds by Jiangsu Deyuan Pharmaceutical Co., Ltd. It includes specific information about the amounts raised in 2017 and 2021, the timing of fund receipt, the establishment of special accounts for the funds, detailed tables comparing committed and actual investment amounts, changes in the use of funds, and the status of projects funded by these proceeds. The document references regulatory requirements from the China Securities Regulatory Commission and the Beijing Stock Exchange, and it includes attachments with detailed financial and project data. The content is focused on the actual use and management of capital raised through stock issuance, which aligns with the definition of a Capital/Financing Update (CAP). It is not an announcement of a report publication, nor is it a general regulatory filing or an annual/interim report. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length and detail support a high confidence score.
2022-01-09 Chinese
关于向特定对象发行股票预案的提示性公告
Capital/Financing Update Classification · 95% confidence The document is a short announcement (654 characters) regarding a company's plan to issue shares to specific investors. It mentions board and supervisory meetings approving the proposal and references related documents disclosed on the stock exchange website. It explicitly states that this announcement does not represent approval or confirmation by regulatory authorities and that the plan is subject to shareholder and regulatory approvals. There are no financial statements or detailed financial data included. The document is a notice about a capital raising plan, specifically a share issuance proposal, rather than the full detailed report or financial results. According to the definitions, this fits the category of Capital/Financing Update (CAP).
2022-01-09 Chinese
关于本次向特定对象发行股票不存在直接或通过利益相关方向参与认购的投资者提供财务资助或补偿的公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement from Jiangsu Deyuan Pharmaceutical Co., Ltd. regarding a specific stock issuance to designated investors. It explicitly states that the company does not provide financial assistance or compensation to investors participating in the subscription. The content focuses on the company's capital raising activity through a targeted stock issuance and clarifies the absence of financial guarantees or compensation. The document length is short (529 characters), and it is an announcement related to capital structure changes rather than a full financial report or detailed financing update. Therefore, it fits best under the category of Capital/Financing Update (CAP).
2022-01-09 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.